Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects

In Gyu Hwang,Jung Hun Kang,Sung Yong Oh,Suee Lee,Sung Hyun Kim,Ki-Hoon Song,Choonhee Son,Min Jae Park,Myung-Hee Kang,Hoon-Gu Kim,Jeeyun Lee,Young Suk Park,Jong Mu Sun,Hyun Jung Kim,Chan-Kyu Kim,Seong Yoon Yi,Joung-Soon Jang,Keunchil Park,Hyo-Jin Kim

Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects

2016

In Gyu Hwang
Jung Hun Kang
Sung Yong Oh
Suee Lee
Sung Hyun Kim
Ki-Hoon Song
Choonhee Son
Min Jae Park
Myung-Hee Kang
Hoon-Gu Kim
Jeeyun Lee
Young Suk Park
Jong Mu Sun
Hyun Jung Kim
Chan-Kyu Kim
Seong Yoon Yi
Joung-Soon Jang
Keunchil Park
Hyo-Jin Kim

Purpose The efficacy of erlotinib, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer (PC). In the present study, we evaluated the effect of epidermal growth factor (EGF) ointment on erlotinib-related skin effects (ERSEs).

Keywords:

Epidermal Growth Factor Ointment
Epidermal growth factor
Intensive care medicine
Cell
Medicine
Epidermal growth factor receptor
Erlotinib
Lung cancer
Pancreatic cancer
Cancer research
Internal medicine
Endocrinology
Tyrosine-kinase inhibitor
Cancer
Dermatology
Common Terminology Criteria for Adverse Events
Gastroenterology
Physical therapy
Rash

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations